Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | DRD4 | P21917 | 2/20 | 0.39 |
| ▸ | DRD3 | P35462 | 2/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.39 |
| ▸ | AMPD2 | Q01433 | 2/20 | 0.38 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22443667 | 1.00 | GAA (0.41) | GAAELANEACHEALDH1A1LMNA | |
| SCHEMBL22443677 | 1.00 | GAA (0.41) | GAAELANEACHEALDH1A1LMNA | |
| SCHEMBL22443618 | 0.91 | ALDH1A1 (0.40) | GAAELANEACHEALDH1A1LMNA | |
| SCHEMBL22443728 | 0.91 | ALDH1A1 (0.40) | GAAELANEACHEALDH1A1LMNA | |
| SCHEMBL22443617 | 0.91 | ALDH1A1 (0.40) | GAAELANEACHEALDH1A1LMNA | |
| SCHEMBL22443392 | 0.78 | ALDH1A1 (0.40) | ACHEALDH1A1DRD2DRD4DRD3 | |
| SCHEMBL22443391 | 0.78 | ALDH1A1 (0.40) | ACHEALDH1A1DRD2DRD4DRD3 | |
| SCHEMBL22453781 | 0.75 | VEGFA (0.40) | GAAACHESIGMAR1 | |
| SCHEMBL22444151 | 0.74 | SIGMAR1 (0.42) | GAAACHEHSD11B1AMPD2SIGMAR1 | |
| SCHEMBL22444194 | 0.74 | SIGMAR1 (0.42) | GAAACHEHSD11B1AMPD2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220152004-A1 | HETEROCYCLYL(PHENYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2022-05-19 | — | — | US | disclosed |
| EP-3941468-A1 | HETEROCYCLYL(PHENYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA | Atrogi AB (SE) | 2022-01-26 | — | — | EP | disclosed |
| CN-113784953-A | Heterocyclyl (phenyl) carbinol compounds useful for treating hyperglycemia | 阿托基公司 | 2021-12-10 | — | — | CN | disclosed |
| WO-2020188301-A1 | HETEROCYCLYL(PHENYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2020-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220152004-A1 | HETEROCYCLYL(PHENYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA | GPR119, SLC5A1, SLC5A2 | GAA 250/4885ELANE 3572/4885ACHE 1623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.